Single-cell tumor-immune microenvironment of BRCA1/2 mutated high-grade serous ovarian cancer.
Launonen IM, Lyytikäinen N, Casado J, Anttila EA, Szabó A, Haltia UM, Jacobson CA, Lin JR, Maliga Z, Howitt BE, Strickland KC, Santagata S, Elias K, D’Andrea AD, Konstantinopoulos PA, Sorger PK, Färkkilä A.
Nat Commun. 2022 Feb 11;13(1):835. doi: 10.1038/s41467-022-28389-3.
Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.
Park J, Kim SI, Jeong SY, Kim Y, Bookman MA, Kim JW, Kim BG, Lee JY.
Gynecol Oncol. 2022 Feb 10:S0090-8258(22)00086-5. doi: 10.1016/j.ygyno.2022.02.002. Epub ahead of print.